Bruker Introduces High-Throughput Sample-to-Answer Molecular Diagnostics System

Bruker Corporation’s Microbiology & Infection Diagnostics division has launched in Europe the MyGenius PRO, a fully automated, sample-to-answer (S2A) molecular diagnostics system based on PCR (Polymerase Chain Reaction) technology.

Designed for infectious disease diagnostics, the new S2A system enables higher throughput, continuous loading of samples, consumables, and reagents, and supports random-access operation. Like the successful medium-throughput BeGenius system, which excels at assay and sample matrix flexibility, the new higher-throughput MyGenius PRO automates the entire workflow—from patient sample to diagnostic result—enhancing laboratory efficiency and supporting higher-throughput volume testing needs, according to the company.

The MyGenius PRO IVDR menu includes (at launch) assays for Cytomegalovirus (CMV) and Epstein-Barr virus (EBV) from whole blood, and BK virus (BKV) from urine, supporting diagnostic testing in immunocompromised patients. Rapid menu expansion, including Human Immunodeficiency Virus type 1 (HIV-1), Hepatitis B virus (HBV), Hepatitis C virus (HCV), Human Herpesvirus 6 (HHV-6) IVDR assays, and additional sample matrices, are planned throughout 2026.

The MyGenius PRO platform was developed by ELITechGroup (a Bruker company) and Hitachi High Tech-Corporation, combining complementary expertise in molecular assays, automation, and engineering. Hitachi High-Tech will introduce the platform under the tradename LABOSPECT GA-5 in Japan. This system comes with Bruker molecular diagnostic assays for infectious disease testing in accordance with Japanese diagnostic regulations.

During a recent interview, AMCLI (Italian Association of Clinical Microbiologists) President Dr. Pierangelo Clerici emphasized the importance of high throughput in microbiology laboratories: “Timely diagnosis is critical in microbiology and virology. Fully automated sample-to-result solutions improve turnaround time and support faster clinical response and effective infection monitoring, while enabling laboratories to streamline workflows and ensure compliance with IVDR regulations,” he said.

MyGenius PRO’s launch marks a new chapter in Bruker’s Microbiology & Infection Diagnostics molecular diagnostics strategy, further expanding a portfolio that includes InGenius, BeGenius, a growing CE-IVD assay menu, and LiquidArray assays for advanced multiplexing and more affordable syndromic panel testing.

Bruker is enabling scientists and engineers to make breakthrough post-genomic discoveries and develop new applications that improve the quality of life. Bruker’s high-performance scientific instruments and high-value analytical and diagnostic solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. In close cooperation with customers, Bruker enables innovation, improved productivity, and customer success in post-genomic life science molecular and cell biology research, in applied and biopharma applications, in microscopy and nanoanalysis, as well as in industrial and cleantech research, and next-generation semiconductor metrology in support of artificial intelligence (AI). Bruker offers differentiated, high-value life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology and molecular diagnostics.

Headquartered in Tokyo, Hitachi High-Tech is engaged in activities in various fields, including the manufacture and sale of clinical analyzers, biotechnology products, radiation therapy systems, semiconductor manufacturing equipment, analytical instruments, and analysis equipment. Hitachi High-Tech also provides high-value-added solutions in industrial fields.